台康生（6589）2日公告，第二代治疗早期乳癌、转移性乳癌的生物相似药EG1206A，已成功向台湾TFDA申请三期临床试验，该新药已获美国FDA核准执行三期临床，由于採多国多中心试验，将陆续向各国提出申请。 专攻乳癌药物开发的台康生，目前持续多项生物药品以及生物相似药 同步往前开发，一系列HER2阳性乳癌产品组合包括第二代HER2阳性标 靶抗体药物Pertuzumab生物相似药EG1206A，预期 ...

FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer. The FDA accepted for review a biologics license application (BLA) seeking the approval ...

This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. A Life Cycle Assessment was conducted to compare the environmental impacts of IV ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

February 26, 2025Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.85. Operator: Hello. Welcome to Vir Biotechnology’s Fourth Quarter and Full Year ...

Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc Mark Eisner; Executive Vice President & Chief Medical Officer; Vir Biotechnology Inc Jason O'Byrne; Executive Vice ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatment technologies have opened new avenues for ...

According to the National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines, the standard-of-care first-line regimen for patients with HER2-positive recurrent/metastatic breast ...

For HER2-positive cancers, the guidelines advocate for dual-target therapies such as trastuzumab and pertuzumab, along with the introduction of pyrotinib in combination with trastuzumab as a novel ...

With stage IV, the breast cancer has spread to other parts of your body. Often the bones, brain, lungs, or liver are affected. Because multiple areas may be involved, focused treatments like ...

Impax Laboratories and Dr. Reddy’s have settled their patent infringement dispute over Rytary, a medication used to treat Parkinson’s disease. Southeastern Grocer's president and CEO and C&S ...